Učitavanje...
4CPS-099 Nivolumab: clinical experience in a tertiary hospital
BACKGROUND: Nivolumab is a human immunoglobulin G4 monoclonal antibody, which binds to the programmed death-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is approved for melanoma, renal, urhotelial, non-small cell lung cancer (NSCLC) and other types of cancer. PURPOSE: To evaluate t...
Spremljeno u:
| Izdano u: | Eur J Hosp Pharm |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Group
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535528/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.190 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|